January 2017, Volume 3, Issue 1

This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.

December 2016, Volume 2, Issue 12

This issue features a look at the 2016 ASH Mentor Awards, a preview of the ASH Annual Meeting, the challenges of designing a clinical trial that is both internally and externally valid, and more.

November 2016, Volume 2, Issue 11

This issue examines challenges related to obtaining insurance coverage for bone marrow transplants in older adults, discusses how to prepare for an educational or scientific presentation, and more.

Focus on Rare Diseases (October 2016, Volume 2, Issue 10.1)

This supplement features FDA updates, clinical trials, policy updates, and the latest research in hematologic rare diseases.

October 2016, Volume 2, Issue 10

This issue looks at the pros and cons of open-access publishing, features updates from the ASH Meeting on Hematologic Malignancies, and shares tips for incorporating small-group instruction.

Focus on Trainees & Fellows (September 2016, Volume 2, Issue 9.1)

This special edition features advice and resources for trainees and fellows.

September 2016, Volume 2, Issue 9

This issue discusses transitioning pediatric patients to the adult system, features an interview between ASH and ABIM about MOC, and provides coverage from the ASH Workshop on Genome Editing.

August 2016, Volume 2, Issue 8

This issue examines the use of companion diagnostics, features patient education on acute myeloid leukemia, and provides coverage from the 2016 ASH Meeting on Lymphoma Biology.

July 2016, Volume 2, Issue 7

This issue looks at online ratings for doctors, features coverage from the 2016 ASCO Annual Meeting, and debates the use of FLT3 inhibitors in older patients with AML.

June 2016, Volume 2, Issue 6

This issue features an inside look at the National Cancer Moonshot Initiative and updates from the American Association for Cancer Research Annual Meeting.

Current Issue

March 2018, Volume 4, Issue 4

This issue features a debate over whether CPX-351 can be used with other therapies in AML, a look at contract research organizations, and more.